Renaissance Group LLC Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Renaissance Group LLC boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 54.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,539 shares of the medical equipment provider's stock after buying an additional 17,789 shares during the quarter. Renaissance Group LLC owned approximately 0.07% of Lantheus worth $4,521,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D lifted its stake in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after acquiring an additional 115 shares during the period. Bleakley Financial Group LLC raised its holdings in Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. lifted its position in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after purchasing an additional 132 shares during the period. Foundry Partners LLC boosted its stake in shares of Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. increased its position in shares of Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded up $3.49 during midday trading on Friday, hitting $102.00. 732,023 shares of the stock traded hands, compared to its average volume of 956,217. Lantheus Holdings, Inc. has a one year low of $59.56 and a one year high of $126.89. The business has a 50 day moving average price of $94.00 and a two-hundred day moving average price of $95.56. The company has a market cap of $6.98 billion, a PE ratio of 16.97 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,109 shares of company stock valued at $6,110,806. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on LNTH. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Finally, Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.